These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30824946)

  • 21. Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
    Ichikawa T; Machida N; Sasaki H; Tenmoku A; Kaneko H; Negishi R; Oi I; Fujino MA
    Oncology; 2016; 91(6):317-330. PubMed ID: 27784014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization.
    Gabr A; Abouchaleh N; Ali R; Vouche M; Atassi R; Memon K; Asadi AA; Baker T; Caicedo JC; Desai K; Fryer J; Hickey R; Abeccassis M; Habib A; Hohlastos E; Ganger D; Kulik L; Lewandowski RJ; Riaz A; Salem R
    Eur J Radiol; 2017 Aug; 93():100-106. PubMed ID: 28668402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Albumin - bilirubin (ALBI) versus Child-Turcotte-Pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy.
    Su TS; Yang HM; Zhou Y; Huang Y; Liang P; Cheng T; Chen L; Li LQ; Liang SX
    Radiat Oncol; 2019 Mar; 14(1):50. PubMed ID: 30917853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization.
    Lee JS; Lee HA; Jeon MY; Lim TS; Kim BK; Park JY; Kim DY; Ahn SH; Um SH; Han KH; Seo YS; Kim SU
    Eur J Gastroenterol Hepatol; 2020 Jun; 32(6):739-747. PubMed ID: 31764406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
    Wang Y; Chen Y; Ge N; Zhang L; Xie X; Zhang J; Chen R; Wang Y; Zhang B; Xia J; Gan Y; Ren Z; Ye S
    Ann Surg Oncol; 2012 Oct; 19(11):3540-6. PubMed ID: 22532305
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
    Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
    Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab.
    Campani C; Bamba-Funck J; Campion B; Sidali S; Blaise L; Ganne-Carrié N; Demory A; Sutter O; Larrey E; Evain M; Ghannouchi H; Wagner M; Marra F; Sutton A; Allaire M; Nault JC
    Liver Int; 2023 Mar; 43(3):708-717. PubMed ID: 36444741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. α-Fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation.
    Zhang Q; Shang L; Zang Y; Chen X; Zhang L; Wang Y; Wang L; Liu Y; Mao S; Shen Z
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):544-52. PubMed ID: 24614696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review.
    Bannaga A; Arasaradnam RP
    World J Gastroenterol; 2020 Sep; 26(33):5022-5049. PubMed ID: 32952347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Patients with Unresectable Hepatocellular Carcinoma Treated with Radioembolization.
    Sukato DC; Tohme S; Chalhoub D; Han K; Zajko A; Amesur N; Orons P; Marsh JW; Geller DA; Tsung A
    J Vasc Interv Radiol; 2015 Jun; 26(6):816-24.e1. PubMed ID: 25824315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic Role of Blood Tumor Markers in Predicting Hepatocellular Carcinoma in Liver Cirrhosis Patients Undergoing Liver Transplantation.
    Kim Y; Park YH; Hwang S; Kim KH; Ahn CS; Moon DB; Ha TY; Song GW; Jung DH; Park GC; Lee SG
    Ann Transplant; 2016 Oct; 21():660-667. PubMed ID: 27777395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.
    Memon K; Kulik L; Lewandowski RJ; Wang E; Ryu RK; Riaz A; Nikolaidis P; Miller FH; Yaghmai V; Baker T; Abecassis M; Benson AB; Mulcahy MF; Omary RA; Salem R
    J Hepatol; 2012 May; 56(5):1112-1120. PubMed ID: 22245905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of the albumin-bilirubin grade for predicting prognosis after curative resection of patients with early-stage hepatocellular carcinoma.
    Ma XL; Zhou JY; Gao XH; Tian L; Wu J; Zhang CY; Zhou Y; Dai Q; Wang BL; Pan BS; Yang XR; Guo W
    Clin Chim Acta; 2016 Nov; 462():15-22. PubMed ID: 27520748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative serum α-fetoprotein and prognosis after hepatectomy for hepatocellular carcinoma.
    Yang SL; Liu LP; Yang S; Liu L; Ren JW; Fang X; Chen GG; Lai PB
    Br J Surg; 2016 May; 103(6):716-724. PubMed ID: 26996727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization.
    Xing M; Kokabi N; Camacho JC; Kim HS
    BMC Cancer; 2018 Jan; 18(1):75. PubMed ID: 29329568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Albumin-Bilirubin (ALBI) Grade-based Prognostic Model For Patients With Hepatocellular Carcinoma Within Milan Criteria.
    Ho SY; Liu PH; Hsu CY; Hsia CY; Su CW; Huang YH; Lei HJ; He YJ; Hou MC; Huo TI
    Am J Clin Oncol; 2019 Sep; 42(9):698-704. PubMed ID: 31335351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined AFP-CRUT with microvascular invasion accurately predicts mortality risk in patients with hepatocellular carcinoma following curative liver resection.
    Huang GQ; Zhu GQ; Huang S; You J; Shi KQ; Hu B; Ruan LY; Zhou MT; Braddock M; Zheng MH
    Expert Rev Gastroenterol Hepatol; 2015; 9(8):1127-38. PubMed ID: 26186642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET.
    Sabet A; Ahmadzadehfar H; Bruhman J; Sabet A; Meyer C; Wasmuth JC; Pieper CC; Biersack HJ; Ezziddin S
    Nuklearmedizin; 2014; 53(2):39-45. PubMed ID: 24777354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.